Drug Companies Protecting Their Monopoly To Keep Prices High

07-11-2016 Blog PostsMediaPress Release

Our new board game illustrates how pharmaceutical companies have a monopoly on the current pricing system and the different ways they keep prices high.

CSRxP Statement on the Costly New Abuse-Deterrent Drug Provision

07-8-2016 Blog PostsMediaPress Release

“With this provision, policymakers are rewriting the rules to benefit pharmaceutical manufacturers for slightly tweaking their product and reintroducing it as a new ‘innovation,’” CSRxP Executive Director John Rother said.

Market-Based Solutions to Address Soaring Drug Prices

07-8-2016 Blog PostsPress Release

Join the Campaign for Sustainable Rx Pricing on Capitol Hill for a discussion about market-based policy solutions to curb rising drug prices.

CSRxP Statement on AstraZeneca seeking “Orphan Drug” designation for widely-used cholesterol drug Crestor

06-30-2016 Blog PostsPress Release

“Abusing rules and regulations to keep competitors out of the market is common in the prescription drug industry, but AstraZeneca’s latest undertaking is especially egregious.”

CSRxP Statement on New Data Showing Best-Selling Drug Prices Rising at Twice the Rate of Inflation

06-30-2016 Blog PostsPress Release

“When the sticker price for 30 out of 39 of the most sold drugs goes up by more than double the rate of inflation, consumers are left holding the bag. These price increases year after year compound the problem and the whole scheme is unsustainable.”

CSRxP Statement on Medicare Trustees Report

06-22-2016 Blog PostsMediaPress Release

“Prescription drug costs are rising much faster than other parts of Medicare and putting ever greater financial pressure on the program and on its beneficiaries. It’s no wonder that voters are making prescription drug prices a top issue in this election.”

CSRxP Announces Support for Bipartisan CREATES Act

06-20-2016 Blog PostsMediaPress Release

The Campaign for Sustainable Rx Pricing (CSRxP) announced its endorsement of the Creating and Restoring Equal Access to Equivalent Samples (“CREATES”) Act, a bill introduced today in the Unites States Senate.

John Rother Statement on MEDPAC Report

06-15-2016 Blog PostsMediaPress Release

“This MEDPAC report confirms exactly what we have been saying: rising drug prices are putting a colossal burden on America’s health care system and now total nearly 20 percent of health care spending. Without market-based solutions like transparency, competition, and value, we can only expect the problem to get worse.”

Statement on Senators’ Probe of Opioid Overdose Treatment Price Spikes

06-10-2016 Blog PostsMediaPress Release

“The pharmaceutical industry’s habit of hiking prices on life-saving medications is appalling. Our campaign has been active in drawing attention to the price spikes on naloxone and we welcome this bipartisan effort to expose pharma’s price gouging tactics.”

American Gastroenterological Association Joins Campaign for Sustainable Rx Pricing

06-8-2016 Blog PostsPress Release

The American Gastroenterological Association announced today that it has joined the Campaign for Sustainable Rx Pricing, a broad-based campaign working to curb rising drug costs. AGA, which has 16,000 members involved in all aspects of gastroenterology around the globe, adds its voice to the hospitals, physicians, pharmacists, nurses, health plans, patients, and employers already promoting CSRxP’s solutions of transparency, competition, and value in the prescription drug market.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.